ALL PRODUCTS NEW ITEMS Antidepressants Modiodal / Modafinil Xenical Anti-Asthmatics Dementia-Alzheimer's Antibiotics-Antivirals Zyban Champix Ro-Accutane HGH Birth Control Antipsychotics Dopamine Agonists Mood Stabilizers Viagra - Cialis Avodart - Proscar AntiEstrogens/Clomid Rasagiline (Azilect)

Aura  Pharmaceutical  Specialties

   
Home
Contact Us
Our Service
ALL PRODUCTS
Bookmark and Share
NEW ITEMS
Norvasc (amlodipine)
Lipitor (atorvastatin)
Lasix (furosemide)
Nexium (esomeprazole)
Fosamax (alendronate)
Glucophage (metformin)
Buspon - Buspar  (buspirone)
Insidon  (opipramol)
Atarax - Vistaril  (hydroxyzine )
Lustral - Zoloft(sertaline)
Abilify (aripiprazole)
Solian (amisulpride)
Zyprexa (olanzapine)
Risperdal (risperidone)
Seroquel (quetiapine)
Antipsychotics
Acne Treatment
Accutane - Roaccutane
Antivirals
Tamiflu (oseltamivir)
MAO-B Inhibitors
Azilect (rasagiline)
Selegiline (deprenyl)
Obesity / Weight Loss
Xenical (orlistat)
Antidepressants
Atarax (hydroxyzine)
Buspon - Buspar (buspirone)
Cipram (citalopram)
Cipralex (escitalopram)
Edronax (reboxetine)
Aurorix (moclobemide)
Stablon (tianeptine)
Lustral - Zoloft (sertaline)
Ixel (milnacipran)
Effexor (venlafaxine)
Desyrel (trazodone)
Paxil (paroxetine)
Wellbutrin XL(bupropion)
Cymbalta (duloxetine)
Dopamine Agonists
Dostinex (cabergoline)
Cabaser (cabergoline)
Trivastal - Ret (piribedil)
Contraceptives
Diane 35
Yasmin
Lo/Ovral
Men's Health
Flomax (tamsulosin)
Propecia (finasteride)
Proscar (finasteride)
Avodart (dutasteride)
Levitra (vardenafil HCL)
Viagra (sildenafil)
Cialis (tadalafil)
Smoking Aid
Zyban (bupropion)
Champix - Chantix
Anti-Estrogens
Arimidex (anastrozole)
Nolvadex (tamoxifen)
Pain - Migraine
Zomig (zolmitriptan)
Mood Stabilizers / Epilepsy
Lamictal (lamotrigine)
Neurontin (gabapentin)
Share |


 

 

Recent Pat CNS Drug Discov. 2006 Jan;1(1):29-41.

Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression.

Brink CB, Harvey BH, Brand L.

Division of Pharmacology, North-West University (PUK), Potchefstroom, 2520, South Africa. fklcbb@puknet.puk.ac.za

Abstract


Tianeptine, an atypical antidepressant patented and developed by Servier, enhances the synaptic reuptake of serotonin, without affecting norepinephrine and dopamine uptake, while it lacks affinity for neurotransmitter receptors. This mechanism for an antidepressant is apparently paradoxical, since the currently employed antidepressants enhance serotonin by inhibiting its breakdown or by inhibiting monoaminergic reuptake. Although tianeptine has been shown to reduce central 5HT availability and to indirecty modulate central adrenergic and dopaminergic systems and to indirectly inhibit cholinergic hyperactivity, its antidepressant action is believed to be more directly related to central neuronal remodeling and restoration of neuronal plasticity. In reliable animal models of depression tianeptine has been shown to prevent neurodegeneration and decreases in hippocampal volume in response to chronic stress. These effects on neuroplasticity are suspected to involve the normalization of the hypothalamic-pituitary-adrenal axis and modulatory effects on excitatory amino acids and N-methyl-D-aspartate receptors. Together with a body of related studies, these data provide further support for the hypothesis that depression may involve dysregulation of pathways controlling cellular resilience and that treatment should be directed towards the reversal thereof. Importantly, tianeptine is not anxiogenic and has also been shown to be effective in treatment-resistant depression, which may lead the way to a major breakthrough in the treatment of depression.

PMID: 18221189 [PubMed - indexed for MEDLINE]

 

Source: PUBMED                                  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

• Home • Refund Policy • Disclaimer • Delivery • Contact Us • Privacy Policy • ALL PRODUCTS •
Copyright © 2002-2011 Aura Pharmaceutical Specialties